CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to enhance cancer immunotherapy by using chemical mutagenesis to modify nanobodies that target the HER2 protein and PD-1 receptor. The goal is to improve the effectiveness of existing treatments against cancer resistance, providing a non-aggressive alternative to traditional chemotherapy.
Finding a non-aggressive treatment against Cancer is one of the most important challenges that medicine has nowadays.
Immunotherapy has emerged as one of the best options to overcome the current problems of chemotherapy.
By the use of monoclonal antibodies (mAb), immunotherapy is able to block regulatory checkpoints and, therefore, the immune response against tumoral cells could be modulated.
Trastuzumab, pembrolizumab and nivolumab are some of the mAb approved by the Food and Drug Administratio…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
